Similar articles

Abstract: Objective: adrenocortical carcinoma (ACC) is a rare but highly malignant tumor, and its diagnosis is mostly delayed and prognosis is poor. We report estrogen receptor (ER) expression in this tumor and our clinical experiences with 17 ACC cases. Methods: The data of the 17 patients (9 females and 8 males, age range from 16 to 69 years, mean age of 42.6 years) with ACC were reviewed, and symptoms, diagnostic procedures, treatment, and results of follow-up were evaluated. Immunohistochemistry was used to detect ER expression in tumor samples from the 17 patients. Results: At the time of diagnosis, 4 tumors were classified as Stage I, 4 as Stage II, 3 as Stage III, and 6 as Stage IV. Eight patients demonstrated positive nuclear immunostaining of ER. The prognosis of patients with ER positive was significantly better (P<0.05) than that of patients with ER negative, with 1- and 5-year survival rates at 86% and 60% for ER-positive patients, and 38% and 0% for ER-negative patients, respectively. Conclusion: ER-positivity may be one of the factors associated with a worse prognosis of ACC.

[1] Allolio, B., Fassnacht, M., 2006. Adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab., 91(6): 2027-2037.

[2] Chen, D.Y., Sosa, R.E., Scherr, D.S., 2004. Treatment of adrenocortical carcinoma: contemporary outcomes. Current Urology Reports, 5(1):65-72.

[3] Colletti, R.B., Roberts, J.D., Devlin, J.T., Copeland, K.C., 1989. Effects of tamoxifen on insulin-like growth factor 1 in patients with breast cancer. Cancer Res., 49(7): 1882-1884.

[4] Dackiw, A.P., Lee, J.E., Gagel, R.F., Evans, D.B., 2001. Adrenal cortical carcinoma. World J. Surg., 25(7):914-926.

[5] Demeure, M.J., Somberg, L.B., 1998. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies. Surg. Oncol. Clin. N. Am., 7(4):791-805.

[6] Dickson, R.B., Lippman, M.E., 1987. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr. Rev., 8(1):29-43.

[7] Lingappa, V.R., Farey, K., 2001. Physiological Medicine: A Clinical Approach to Basic Medical Physiology. McGraw-Hill, p.584.

[8] MacFarlane, D.A., 1958. Cancer of the adrenal cortex: the natural history, prognosis and treatment in the study of fifty-five cases. Ann. R. Coll. Surg. Engl., 23(3):155-186.

[9] Medeiros, L.J., Weiss, L.M., 1991. New development in the pathologic diagnosis of adrenal cortical neoplasms: a review. Am. J. Clin. Pathol., 97(1):73-83.

[10] Ng, L., Libertino, J.M., 2003. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J. Urol., 169(1):5-11.

[11] Osborne, C.K., Boldt, D.H., Clark, G.M., Trent, J.M., 1983. Effects of tamoxifen on human breast cancer cell kinetics: accumulation of cells in early G1 phase. Cancer Res., 43(8):3583-3585.

[12] Pommier, R.F., Brennan, M.F., 1992. An eleven-year experience with adrenocortical carcinoma. Surgery, 112(6): 963-970.

[13] Schteingart, D.E., Doherty, G.M., GAuger, P.G., Giordano, T.J., Hammer, G.D., Korobkin, M., Worden, F.P., 2005. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr. Relat. Cancer, 12(3):667-680.

[14] Schulick, R.D., Brennan, M.F., 1999. Adrenocortical carcinoma. World J. Urol., 17(1):26-34.

[15] Sullivan, M., 1978. Adrenal cortical carcinoma. Urology, 120(6):660-665.

[16] Weiss, L.M., 1984. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol., 8(3):163.